Mirador Therapeutics closed a $250 million Series B to advance a precision-immunology portfolio and signaled plans to consider an IPO later in the year. The financing will fund continued clinical development and platform expansion as the company pushes toward registration-enabling studies, according to an Endpoints News report. Investors centered the round on Mirador’s pipeline targeting immune-mediated diseases; the cash haul positions the company to accelerate multiple programs and increases the likelihood of a public offering if clinical data readouts are favourable. The raise also exemplifies strong late-stage private financing appetite for immunology plays ahead of JPM and potential 2026 listings.